ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

• Status: Completed
• Trial end date: 2007-12-01

Summary

This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.

• Phase: Phase 2

Details

• Lead Sponsor: Amgen
• Treatments: Cyclophosphamide; Darbepoetin alfa; Doxorubicin; Paclitaxel